Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Brigitta G. Baumert(Maastricht University Medical Centre), Monika E. Hegi(University of Lausanne), Martin J. van den Bent(Erasmus MC Cancer Institute), Andreas von Deimling(German Cancer Research Center), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Khê Hoang‐Xuan(Sorbonne Université), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Guy Kantor(Institut Bergonié), Martin J B Taphoorn(Leiden University), Mohamed Ben Hassel(Centre Eugène Marquis), Christian Hartmann(German Cancer Research Center), Gail Ryan(Peter MacCallum Cancer Centre), David Capper(German Cancer Research Center), Johan M. Kros(Erasmus MC Cancer Institute), Sebastian Kurscheid(Australian National University), Wolfgang Wick(German Cancer Research Center), Roelien H. Enting(University of Groningen), Michele Reni(Vita-Salute San Raffaele University), Brian Thiessen(BC Cancer Agency), F. Dhermain(Institut Gustave Roussy), Jacoline E. C. Bromberg(Erasmus MC Cancer Institute), L. Feuvret(Sorbonne Université), Jaap C. Reijneveld(Amsterdam UMC Location University of Amsterdam), Olivier Chinot(Aix-Marseille Université), Johanna M. M. Gijtenbeek(Radboud University Nijmegen), John P. Rossiter(Queen's University), Nicolas Dif(European Organisation for Research and Treatment of Cancer), Carmen Balañá(Hospital Universitari Germans Trias i Pujol), Jose Bravo-Marques(IPO Porto), Paul M. Clément(KU Leuven), Christine Marosi(Medical University of Vienna), Tzahala Tzuk-Shina(Rambam Health Care Campus), Robert Nordal(University of Calgary), Jeremy Rees(National Hospital for Neurology and Neurosurgery), Denis Lacombe(European Organisation for Research and Treatment of Cancer), Warren Mason(University of Toronto), Roger Stupp(University Hospital of Zurich)
Cited by 497Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis